Vivos Therapeutics(VVOS.US)

Last Updated 19:00:00 ET
longbridge loading

TRAW Q1'26 Earnings: EPS estimate is (0.56) USD

TradingView·
US
TRAW
+0.75%
US
VHT
+0.22%
US
PBE
+1.37%
TradingView·
US
TRAW
+0.75%
US
VHT
+0.22%
US
PBE
+1.37%

12 Health Care Stocks Moving In Thursday's Intraday Session

benzinga_article·
US
LIMN
-1.53%
US
CDNA
+2.78%
US
QDEL
+4.13%
benzinga_article·
US
LIMN
-1.53%
US
CDNA
+2.78%
US
QDEL
+4.13%

Vivos Therapeutics shares are trading lower after the company reported worse-than-expected Q4 financial results.

benzinga_article·
US
VVOS
+2.85%
US
XHE
+2.08%
US
XLV
-0.14%
benzinga_article·
US
VVOS
+2.85%
US
XHE
+2.08%
US
XLV
-0.14%

Vivos Therapeutics Inc Full Year Sales Increase

nasdaq·
US
VVOS
+2.85%
US
IHI
+1.20%
US
XLV
-0.14%
nasdaq·
US
VVOS
+2.85%
US
IHI
+1.20%
US
XLV
-0.14%

Vivos Therapeutics | 8-K: FY2025 Revenue: USD 17.44 M

Earnings Watch·
US
VVOS
+2.85%
Earnings Watch·
US
VVOS
+2.85%

12 Health Care Stocks Moving In Wednesday's After-Market Session

benzinga_article·
US
CDNA
+2.78%
US
VVOS
+2.85%
US
EUDA
+15.08%
benzinga_article·
US
CDNA
+2.78%
US
VVOS
+2.85%
US
EUDA
+15.08%

Vivos Therapeutics | 10-K: FY2025 Revenue: USD 17.44 M

Earnings Watch·
US
VVOS
+2.85%
Earnings Watch·
US
VVOS
+2.85%

Vivos Therapeutics releases 2025 financial results, revealing strong performance.

Unusual Whales·
US
VVOS
+2.85%
Unusual Whales·
US
VVOS
+2.85%

Vivos Therapeutics Reports Full Year 2025 Financial Results

GlobeNewswire·
US
VVOS
+2.85%
GlobeNewswire·
US
VVOS
+2.85%

Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call | VVOS Stock News

StockTitan·
US
VVOS
+2.85%
StockTitan·
US
VVOS
+2.85%
© 2026 Longbridge｜Disclaimer